

Ensemble Discovery Names Michael D. Taylor, PhD as President and Chief Executive Officer

Cambridge, MA (September 4, 2007) — Ensemble Discovery Corporation, a biotechnology company developing novel classes of therapeutics and bioassays using its proprietary DNA Programmed Chemistry™ (DPC™) platform, today announced that it has appointed Michael D. Taylor, Ph.D. as President and Chief Executive Officer and to the company's Board of Directors.

“We are thrilled to welcome an experienced executive of Mike's caliber to Ensemble Discovery,” said Noubar Afeyan, Ph.D., Chairman of Ensemble Discovery and Managing Partner and CEO of Flagship Ventures. “Mike brings a wealth of experience in the pharmaceutical industry and a track record of success that will be critical as we further develop our drug discovery and biodetection programs.”

Dr. Taylor has been in the pharmaceutical industry for more than twenty years with extensive experience in drug discovery and development, licensing and business development, and managing R&D alliances with pharmaceutical and biotech partners. Most recently, Dr. Taylor served as Senior Vice President for Pfizer's Global R&D division where he was responsible for global project and portfolio management.

“I am impressed and excited by the scientific achievements made to date at Ensemble. The Company is clearly poised for rapid growth,” said Dr. Taylor. “Our ability to leverage the revolutionary DNA-Programmed Chemistry platform for creation of Programmed Macrocycles and Programmed Bioassays enables commercial access to a range of markets in both therapeutics and diagnostics.”

In other positions with Pfizer (and previously Warner-Lambert/Parke-Davis), Dr. Taylor led discovery, and early- and late-stage development projects across multiple therapeutic areas, including Lipitor® and Neurontin.® He has authored or coauthored 65 articles, reviews, and published abstracts and holds 6 patents.

Dr. Taylor earned a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania.

About Ensemble Discovery

Based in Cambridge, MA, Ensemble Discovery Corporation is harnessing a fundamentally new approach to controlling chemical reactivity to develop novel classes of therapeutics and bioassays. Ensemble Discovery is deploying DNA-Programmed Chemistry (DPC), which is based on the groundbreaking work of Professor David Liu of Harvard University and Howard Hughes Medical Institute. In its drug discovery

programs, Ensemble uses DPC to generate Programmed Macrocycles as drug candidates for challenging pharmaceutical targets. In its diagnostic programs, Ensemble uses DPC to control the generation of detection signals in response to the presence of specific molecular events underlying human diseases. DPC-based assays are particularly adept at the detection of dimeric molecules such as growth factor receptors on cell surfaces.

For a complete description of Ensemble Discovery Corporation, its product programs and its platform technologies, go to www.enssemblediscovery.com.

Media Contact:

Kathryn Morris

845-635-9828

Kathryn@kморrispr.com